Axovan
Drug development company specializing in g protein-coupled receptors.
Launch date
Market cap
-
Enterprise valuation
€67—100m (Dealroom.co estimates Jan 2002.)
Allschwil Canton of Basel-Landschaft (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | N/A | Series A | |
| N/A | $18.3m | Early VC | |
| N/A | N/A | Series B | |
N/A | Acquisition | ||
| Total Funding | €16.6m | ||